论文部分内容阅读
一项在近期的《新英格兰医学杂志》上发表的药物试验结果显示,将GlaxoSmithKline公司开发的抗CD20抗体tositumomab与放射性碘联用的Bexxar治疗方案作为一线疗法用以治疗滤泡性淋巴瘤患者;可有效减缓其病情发展。来自于美国密歇根州立大学Ann Arbor医学中
A recent drug trial published in the New England Journal of Medicine showed that GlaxoSmithKline’s Bexxar treatment, a combination of anti-CD20 antibody tositumomab and radioactive iodine, is used as first-line therapy for patients with follicular lymphoma; It can effectively slow down the progression of the disease. From Ann Arbor Medical at Michigan State University